Loop diuretics in the treatment of hypertension and edema syndrome

Q: What is the clinical evidence from this study?

Study design: Review. Population: Hypertension and edema syndrome. Intervention: Torasemide vs. Furosemide. Primary outcome: Total and cardiovascular mortality.

А. А. Кириченко

doi:10.26442/sg29132

March 15, 2016Systemic HypertensionOpen Access

Loop diuretics in the treatment of hypertension and edema syndrome

View Full Paper

Ask AI

Bookmark

Share

Why the study?

Does torasemide improve clinical outcomes compared to furosemide in patients with hypertension and edema?

Key Points

To compare the pharmacological properties and clinical efficacy of torasemide and furosemide in the management of hypertension and edema.
Evaluated the pharmacokinetics, including bioavailability and elimination half-life, of torasemide versus furosemide.
Assessed therapeutic outcomes in essential hypertension treated with low doses (2.5–5 mg/day) and chronic heart failure treated with 5–20 mg/day.
Torasemide exhibited higher bioavailability (>80%) and a longer half-life (3–4 hours) than furosemide, resulting in smoother diuresis with less rebound effect.
In essential hypertension, non-diuretic doses of torasemide reduced diastolic blood pressure below 90 mm Hg in 70% to 80% of patients.
Patients treated with torasemide experienced lower total and cardiovascular mortality compared to the comparison group (2.2% vs. 4.5%).

Structured PICO

Does torasemide improve clinical outcomes compared to furosemide in patients with hypertension and edema?

P

Population

Patients with hypertension and edema, including chronic heart failure

I

Intervention

Torasemide (2.5-5 mg/day for hypertension, 5-20 mg/day for chronic heart failure)

C

Comparator

Furosemide

O

Outcome

Clinical efficacy, blood pressure reduction, and mortality

Main Result

Absolute Event Rate: 2.2% vs 4.5%

Torasemide offers pharmacological advantages over furosemide, including higher bioavailability and longer half-life, and may be associated with lower mortality in patients with heart failure.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Torasemide-associated lower mortality should not yet change diuretic selection in hypertension; leaves open superiority over furosemide in RCTs.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

А. А. Кириченко (2016) conducted a review in Hypertension and edema syndrome. Torasemide vs. Furosemide was evaluated on Total and cardiovascular mortality.

synapsesocial.com/papers/6a904fad6419f6799027a149 https://doi.org/10.26442/sg29132

View Full Paper

Ask AI

Bookmark

Share

Loop diuretics in the treatment of hypertension and edema syndrome

Key Points

Structured PICO

Main Result

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Loop diuretics in the treatment of hypertension and edema syndrome

Key Points

Structured PICO

Main Result

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading